Translate Bio, Inc. |
10%+ Owner |
Common Stock, par value $0.001 per share |
75.7M |
$2.88B |
$38.00 |
Sep 14, 2021 |
Direct |
MeiraGTx Holdings plc |
10%+ Owner |
Ordinary Shares ($0.00003881 par value per share) |
11.5M |
$73.1M |
$6.36 |
Aug 12, 2024 |
Through its wholly-owned subsidiary, Sanofi Foreign Participations B.V. |
Icosavax, Inc. |
10%+ Owner |
Common Stock (par value, $0.0001) |
3.16M |
$49.4M |
$15.67 |
Aug 2, 2021 |
Through its wholly-owned subsidiary, Aventis Inc. |
MeiraGTx Holdings plc |
10%+ Owner |
Ordinary Shares ($0.00003881 par value per share) |
698K |
$4.44M |
$6.36 |
Aug 12, 2024 |
Through its wholly-owned subsidiary Kadmon Corporation, LLC |
Icosavax, Inc. |
10%+ Owner |
Series A-1 Preferred Stock (par value, $0.0001) |
0 |
|
|
Aug 2, 2021 |
Through its wholly-owned subsidiary, Aventis Inc |
Icosavax, Inc. |
10%+ Owner |
Series B-1 Preferred Stock (par value, $0.0001) |
0 |
|
|
Aug 2, 2021 |
Through its wholly-owned subsidiary, Aventis Inc |